Capecitabine
Estrogen-Receptor Positive Breast Cancer
Explore 74 assets in Estrogen-Receptor Positive Breast Cancer →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
UNC Lineberger Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07340541CT.gov Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies | — | Recruiting | — | — | — |
NCT07222215CT.gov PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) | — | Recruiting | — | — | — |
NCT04901299CT.gov Fulvestrant + Neratinib In Breast Cancer | — | Withdrawn | — | — | — |
NCT04886531CT.gov Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | — | Recruiting | — | — | — |
NCT04965688CT.gov Biology Guided Therapy for Breast Cancer for ER Positive | — | Terminated | — | — | — |
NCT00194792CT.gov Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Estrogen-Receptor Positive Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | UNC Lineberger Comprehensive Cancer Center | P2 | B · 57 |
| Exemestane | National Cancer Institute (NCI) | P4 | BBB |
| Everolimus | UNC Lineberger Comprehensive Cancer Center | P4 | BBB |
| Tamoxifen | Dana-Farber Cancer Institute | P4 | BB |
| Capivasertib | Imperial College London | P2 | BB |
| Palbociclib | Forward Pharmaceuticals Co., Ltd. | P3 | BB |
| Giredestrant | Hoffmann-La Roche | P3 | BB |
| Abemaciclib | Jonsson Comprehensive Cancer Center | P3 | BB |
| Ribociclib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Estrogen-Receptor Positive Breast Cancer cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Estrogen-Receptor Positive Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-estrogen-receptor-positive-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →